Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Rating of “Moderate Buy” by Analysts

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have earned an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $44.25.

Several equities research analysts have recently commented on DMRA shares. Zacks Research raised shares of Damora Therapeutics, Inc. Common Stock to a “hold” rating in a research report on Friday, January 9th. Guggenheim reiterated a “buy” rating and set a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Evercore assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Wednesday. They set an “outperform” rating and a $46.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, December 29th. Finally, UBS Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They issued a “buy” rating and a $45.00 target price on the stock.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Several large investors have recently bought and sold shares of DMRA. Janus Henderson Group PLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth $40,000. Geode Capital Management LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at about $266,000. Virtu Financial LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the third quarter valued at about $49,000. Sigma Planning Corp purchased a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $334,000. Finally, Two Sigma Investments LP purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth approximately $76,000. 14.20% of the stock is currently owned by institutional investors.

Damora Therapeutics, Inc. Common Stock Trading Down 0.5%

DMRA opened at $25.50 on Friday. Damora Therapeutics, Inc. Common Stock has a 1-year low of $2.01 and a 1-year high of $38.33. The company has a market cap of $1.54 billion, a price-to-earnings ratio of -2.11 and a beta of 1.42. The company’s fifty day moving average price is $27.02 and its two-hundred day moving average price is $19.77.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.